Viral persistence / SARS-CoV-2 reservoir

Start here: a fire that looks out but still smolders

Picture a house fire that the crew declares out. The flames are gone and the smoke has cleared, but deep inside a wall a beam keeps smoldering, hot enough to send smoke through the house for weeks. A viral reservoir is that smoldering beam. The acute infection ends and the swab goes negative, while a small amount of virus or viral debris stays embedded in tissue the swab cannot reach.

If that is what is happening, a brief infection can drive a long illness without ever showing up on a standard test. The reservoir would keep prodding the immune system, which would explain the lasting inflammation, fatigue, and other features that define long COVID for many people.

The autopsy evidence

The strongest single piece of evidence comes from autopsies. In a detailed study, SARS-CoV-2 RNA was found widely across the body and persisted in multiple tissue types, including the brain, in some cases out to around 230 days after symptom onset, long after the airway had cleared.¹

This does not prove the leftover virus is still replicating or still causing harm. It does establish the basic fact the reservoir idea rests on: the virus can stay in the body far longer than the week or two of acute illness, and in places routine testing never samples.

moderateautopsy-confirmed persistencepersistence shown, harm not proven

The gut as a holding tank

The gut is the tissue where persistence is best documented. Viral nucleocapsid protein has been found in gastric and intestinal biopsies, and SARS-CoV-2 RNA shows up in stool in a meaningful fraction of people months after infection, correlating with gut symptoms.²

This matters beyond the gut. ACE2, the receptor the virus uses to enter cells, also helps the gut absorb tryptophan, the raw material for serotonin. A gut reservoir can disturb that pathway, which is one proposed route from lingering virus to low serotonin, altered gut bacteria, and the wider symptom picture.

moderatewell-founded associationtissue RNA tied to symptoms, OR 5.17

Does the leftover virus track with being ill

An observation is more convincing when the amount of leftover virus lines up with how sick people are. It often does. Detectable viral RNA in tissue or plasma has been associated with persistent symptoms, with one estimate putting the odds of symptoms about five times higher when tissue RNA is present.³

A large multi-omic study reinforced this from the other direction, identifying viral RNA in the blood early in infection as one of a handful of factors that predicted who would go on to develop long COVID.⁴ Association is not causation, but a dose-response link is exactly what you would expect if the reservoir were driving the illness.

moderatedose-response associationpredictive, not yet causal

The honest gap: clearing it has not yet helped

The cleanest test of the reservoir idea is to clear the virus and see whether people get better. So far that test has not delivered. A randomized trial of an extended antiviral course did not improve long COVID symptoms over placebo.⁵

This is the most important caveat on the whole page. No treatment is approved for long COVID, and the reservoir-targeting trials done so far have not produced a positive readout. A negative trial can mean the wrong drug, the wrong dose, the wrong duration, or the wrong subgroup, rather than a wrong theory. But it keeps the reservoir an unproven cause, not a settled one.

antiviral trial negativeno approved treatmentcause still unproven

How it is being studied

Researchers look for the reservoir in several ways: viral RNA and protein in tissue biopsies, RNA in stool and plasma, and immune signatures that suggest the body is still responding to an antigen. Reviews that pull this evidence together judge the case for a tissue reservoir to be substantial while stopping short of calling it proven.⁶

The practical frontier is the set of antiviral and monoclonal antibody trials aimed at the reservoir. Their results, positive or negative, will do more than any single observation to settle whether persistent virus is a driver of long COVID or a bystander.

What this means for you

If you have long COVID, the reservoir idea offers a coherent reason a short infection could leave a long illness, and it is grounded in real findings: virus that lingers in tissue, gut RNA that tracks with symptoms, and early viral RNA that predicts who gets sick. That is worth knowing, because it counters the claim that nothing physical is going on.

It is just as important to hold the limits honestly. A negative airway swab does not rule a reservoir in or out, no approved treatment targets it yet, and the trials that have tried to clear it have not yet shown a benefit. Be cautious with clinics or products that sell reservoir-clearing cures as proven. The science is promising and unfinished, and those are not the same thing.

References

Each reference links to the source on PubMed, PMC, or the publisher.

1. SARS-CoV-2 is distributed across the body and persists in multiple tissues, including the brain, on autopsy. Nature, 2022.
2. Gut SARS-CoV-2 nucleocapsid protein and fecal RNA persist for months and correlate with gastrointestinal symptoms. Lancet Infectious Diseases, 2024.
3. Tissue and plasma SARS-CoV-2 RNA is associated with persistent symptoms in long COVID. Lancet Infectious Diseases, 2024.
4. A multi-omic study links early viral RNA in blood, among other factors, to later long COVID. Cell, 2022.
5. An extended antiviral course did not improve long COVID symptoms in a randomized trial. Lancet Infectious Diseases, 2025.
6. A review of the evidence for a SARS-CoV-2 tissue reservoir in long COVID. Lancet Infectious Diseases, 2025.